PureTech Health (PRTC) H2 2024 earnings summary

Executive summary

• Achieved major milestones in 2024, including FDA approval of Cobenfy for schizophrenia and successful Phase 2b results for deupirfenidone in IPF, with ongoing open-label extension showing durable efficacy.

• LYT-200 oncology program showed strong clinical data in AML and solid tumors, with multiple complete responses and favorable safety profile.

• Robust financial execution with $366.8 million in cash at year-end 2024 and $339.1 million as of March 31, 2025, supporting operational runway into at least 2027.

• Monetized equity holdings and milestone payments generated $327.4 million, enabling a $100 million shareholder return via tender offer.

• Strategic focus for 2025 includes advancing key programs, exploring external funding, and addressing valuation disconnect.

Financial highlights

• Consolidated revenue rose to $4.8 million in 2024 from $3.3 million in 2023, driven by milestone payments, royalties, and grants.

• Operating loss decreased to $136.1 million in 2024 from $146.2 million in 2023, mainly due to lower R&D expenses.

• Net income of $27.8 million in 2024 versus a net loss of $66.6 million in 2023, primarily from a $151.8 million gain on Seaport deconsolidation.

• Founded entities raised $397.5 million in 2024, with over 88% from third-party investors.

Outlook and guidance

• Intends to discuss deupirfenidone Phase 2b results with FDA by Q3 2025, aiming to initiate Phase 3 trial by year-end.

• Exploring funding options for Phase 3, including spin-out, external equity, project/royalty financing, and partnerships.

• LYT-200 Phase 1b AML/MDS top-line results expected in Q3 2025; seeking third-party financing for next growth phase.

• Additional capital return opportunities to shareholders under evaluation.